Lin Yu-Hsin 4

What Happened

• Lin Yu‑Hsin, CEO of Belite Bio, had an additional 206,954 ordinary shares subject to a previously granted option vest on 2026-03-31. The reported acquisition is a derivative award at $0.00 (i.e., vesting of option rights rather than an open‑market purchase).
• According to the filing, 206,954 shares under the option had previously vested and remained exercisable; with this vesting event, exercisable shares under that option total 413,908. No cash payment or open‑market trade was reported.

Key Details

• Transaction date and price: 2026-03-31; derivative award reported at $0.00 per share (code A).
• Shares affected: 206,954 additional shares vested; 206,954 had previously vested and remain exercisable — total exercisable under the option now 413,908.
• Footnote: Option was granted on 12/23/2020 and vests in installments upon satisfaction of performance criteria; one performance condition was met on 3/31/2026, triggering this vesting.
• Filing: Form 4 filed 2026-04-02 (appears timely given the 3/31 transaction).

Context

• This was a vesting of a performance-based option (a derivative award), not a stock purchase or sale. Vesting makes the underlying optioned shares exercisable in the future; it does not itself change market float unless/until shares are exercised and issued or sold.
• Such awards are typically part of executive compensation and do not, by themselves, indicate a buy or sell sentiment.